Portfolio company
Lycia Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
GlycoEra
This company develops glycoengineered biologics to degrade disease-causing extracellular proteins for patients with autoimmune disorders and other inflammatory conditions.
Avilar Therapeutics
The company develops extracellular protein degraders to treat autoimmune and neurological diseases for patients and healthcare providers.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Odyssey Therapeutics
This biopharmaceutical company develops oral small molecule and protein medicines for patients with autoimmune and inflammatory diseases.
Attovia Therapeutics
The company develops biparatopic biologics to treat patients with immune-mediated diseases and cancer through a modular protein design platform.
Nurix Therapeutics
This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.
LTZ Therapeutics
This biopharma company develops myeloid engager immunotherapies for patients with cancer and autoimmune diseases.